“Navigating Change: Illumina Announces Sale of Grail Following Antitrust Ruling on $7.1 Billion Acquisition”
In a recent development, Illumina Inc. has announced its decision to sell its subsidiary, Grail, following a federal appeals court ruling that deemed the $7.1 billion acquisition in 2021 anticompetitive. Grail specializes in producing a blood test designed to detect early signs of cancer. Illumina, known for its gene-sequencing products, expressed its commitment to a … Read more